Metformin could one day be used to treat malignant tumors

January 16, 2018, Agency for Science, Technology and Research (A*STAR), Singapore

A*STAR researchers have provided strong evidence, using patient tumor grafts, that metformin, a common diabetes drug, might help fight colorectal cancer in humans.

Metformin's potential as a tumor-suppressing agent, to prevent the growth of breast, colon, lung and prostate cancers, has been demonstrated in pre-clinical studies. However, the experimental models used in these studies do not accurately recreate the natural manifestations of the disease, and require toxic levels of to demonstrate beneficial effects.

Min-Han Tan and a group of researchers from A*STAR's Institute of Bioengineering and Nanotechnology (IBN), the Biological Resource Centre, and the Genome Institute of Singapore, with collaborators from hospitals across Singapore, have now tested metformin's cancer-fighting abilities on a model of that is more representative of how the disease appears in humans.

The team took samples of from two patients and implanted them in mice, then assessed how the tumors responded to metformin as well as 5-fluorouracil, the current front-line treatment for colorectal cancer.

They found that metformin inhibited by at least 50 per cent after 24 days and, when combined with 5-fluorouracil, inhibited the tumor grafts from one patient by 85 per cent. The experiments used concentrations of metformin equivalent to that used to treat diabetes in humans.

In previous studies, scientists typically injected cancer cells into host animals rather than transplanting tissue directly. In these models, high glucose, insulin, and growth factor levels are needed to establish cell cultures for injection. Tan's group suspects that this artificial environment meant previous studies needed higher levels of metformin to stunt tumor growth as, in this study, they were able to demonstrate response using therapeutic doses of the drug: "We tested a wide range of concentrations down to the physiological," says Tan. "It was important to show that there was a response at that level, as many studies have not documented that."

The IBN-led collaboration discovered that metformin enacted its therapeutic benefits by activating a cellular pathway implicated in the inhibition of cancer, and by reducing cancer cell oxygen consumption. Using next-generation genetic sequencing, the team also provided evidence that direct patient tissue grafts in mice retain the genetic, molecular, and tissue features of the original tumor—making them ideal platforms to study colorectal cancer and its treatment.

It's believed that this is the first investigation into metformin and colorectal cancer using patient grafts. Tan says that future studies could shed light on metformin's relevance as a therapeutic agent for cancer: "Our study shows that metformin has a possible activity against colorectal , using gold-standard materials, and provides a mechanism to explain this. Further clinical trials are now needed."

Explore further: Diabetes drug metformin inhibits multidrug-resistant breast cancer

More information: Nur-Afidah Mohamed Suhaimi et al. Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient–Derived Xenografts, Molecular Cancer Therapeutics (2017). DOI: 10.1158/1535-7163.MCT-16-0793

Related Stories

Diabetes drug metformin inhibits multidrug-resistant breast cancer

December 6, 2017
The drug metformin, typically prescribed to treat type 2 diabetes, keeps breast cancer cells from developing multiple drug resistance (MDR) and can reverse MDR after it¹s appeared, according to a study published December ...

Metformin confers anti-tumor immunity by reactivating exhausted CD8T lymphocytes

February 24, 2016
Anti-cancer effect of tumor infiltrating CD8+T lymphocyte (CD8TIL) is suppressed by interaction between immune-checkpoint molecules such as PD-1 and CTLA-4 expressed on CD8TIL and their ligands expressed on cancer cells, ...

More side effects with CRT plus metformin in head, neck cancer

May 7, 2017
(HealthDay)—Patients with advanced head and neck cancer undergoing chemoradiotherapy (CRT) and receiving metformin experience more side effects than patients not on metformin, according to research published online April ...

Diabetes drug takes aim at cancer's fuel source

January 25, 2017
In the last three years, researchers have shown that diabetic patients with head and neck cancer, may have better outcomes than non-diabetic patients when they are taking the drug metformin for their diabetes. In order to ...

Study: Metformin for breast cancer less effective at higher glucose concentrations

October 24, 2013
A University of Colorado Cancer Center study published online this month in the journal Cell Cycle shows that breast cancer cell growth, motility and aggression is promoted by excess glucose, as experienced by patients with ...

Recommended for you

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

Loss of protein p53 helps cancer cells multiply in 'unfavourable' conditions

October 17, 2018
Researchers have discovered a novel consequence of loss of the tumour protein p53 that promotes cancer development, according to new findings in eLife.

Researcher fighting breast cancer with light therapy

October 17, 2018
When treatment is working for a patient who is fighting cancer, the light at the end of the tunnel is easier to see.

New method uses just a drop of blood to monitor lung cancer treatment

October 17, 2018
Dr. Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.